November 6, 2024
Also, with a win for the House and Senate to stimulate economic, regulatory and legislative priorities
Earnings today: Ionis Pharmaceuticals (IONS), Lenz Therapeutics (LENZ)
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninform
November 5, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
10 reported (SAGE),(MDXG)(BPMC),(ALNY),(QURE), (BEAM), (RARE), (VERV), (ADVM), (EDIT), (CRSP)- more to report:
Ionis Pharmaceuticals (IONS), Lenz Therapeutics (LENZ) 11/6 Wednesday
Moderna (MRNA), Vericel (VCEL) and AxoGen (AXGN) 11/7 Thursday
Agenus (AGEN), Sage Therapeutics (SAGE), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Voyager Therapeutics (VYGR) 11/12 Tuesday
November 6, 2024
Wednesday’s surge in stocks is not just a reaction to a Trump victory, but also a relief that the election outcome is clear
However, the rally could lose some steam in the coming days as the excitement wears off
Today’s earnings: CRBU, RGNX, IONS, LENZ, SLDB and GBIO (below)
Never leave an investor uninformed!
November 5, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 10 reported (SAGE),(MDXG)(BPMC),(ALNY),(QURE), (BEAM), (RARE), (VERV), (ADVM), (EDIT), (CRSP)- more to report: Ionis Pharmaceuticals (IONS), Lenz Therapeutics (LENZ) 11/6 Wednesday Moderna (MRNA), Vericel (VCEL) and AxoGen (AXGN) 11/7 Thursday Agenus (AGEN), Sage Therapeutics (SAGE), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Voyager Therapeutics (VYGR) 11/12 Tuesday
November 3, 2024
A scorecard of earnings releases of covered companies Reporting to date - 10 The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status".
October 3, 2024
Called “Monetization Financing with DRI Healthcare Trust” as access to capital markets is shaky EDIT sold certain future license fees and other payments owed under its Cas9 license agreement with Vertex Pharmaceuticals (VRTX)to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. EDIT closed down -$0.02 with only a +$0.06 or +1.87% aftermarket indication
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
